Solid Biosciences is trading 5.37% down at $8.10 in pre-market, with no new company-specific announcement identified for August 11, 2026.
- The August 6 earnings release showed generally well-tolerated SGT-003 treatment in 53 participants.
- An updated $200 million equity shelf may remain a dilution overhang, but available coverage does not explicitly connect it to the decline.
- The broadly flat market backdrop offers limited macro explanation.